Investment
Features
FeesSafety
Academy
More
Pluang+

Barclays raises Tower Semiconductor price target to $310 on strong AI and photonics growth.

Analyst Insights
18 Sep 2026
Andrew Wynn
View Source
Bullish
Barclays raises Tower Semiconductor price target to $310 on strong AI and photonics growth.

Barclays set a new price target of $310 for Tower Semiconductor, reflecting a potential 41.4% upside from its current price. This follows Tower Semiconductor's start of high-volume shipments of optical engines for AI infrastructure in partnership with NewPhotonics. The company will also showcase its Silicon Photonics platform at ECOC 2026, emphasizing its focus on AI, LiDAR, and quantum computing sectors. These developments highlight Tower Semiconductor's strong position in high-growth technology markets and have driven recent stock gains.

Tower Semiconductor's recent developments in AI and photonics come as the Technology sector on Pluang shows broad gains, with 92 of 150 stocks rising as of Sep 18, 2026 20:11 WIB. Among notable movers, STM (STMicroelectronics NV) rose 1.85% to USD 49.51 with a typical hold time of 65 days and 100% buy order activity. BILL (Bill.com Holdings Inc) declined 1.74% to USD 48.40 amid 100% sell orders, while APLD (Applied Digital Corporation) gained 1.69% to USD 26.82 with 73% buy orders and a 21-day typical hold time.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
2 hours ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
3 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
3 hours ago
HYPE token hits new all-time high after Hyperliquid enables manual USDC/USDT borrowing with HYPE and Bitcoin collateral.

HYPE token hits new all-time high after Hyperliquid enables manual USDC/USDT borrowing with HYPE and Bitcoin collateral.

HYPE token surged 10.5% to $91.20, reaching a new all-time high of $92.56 after Hyperliquid launched manual borrowing of USDC and USDT using HYPE and Bitcoin as collateral. The platform offers a 65% loan-to-value ratio for HYPE, higher than Bitcoin's...

Market News
Bullish
4 hours ago
CleanTech hires Mercator for independent report on fluorspar project in Kentucky, advancing critical mineral exploration.

CleanTech hires Mercator for independent report on fluorspar project in Kentucky, advancing critical mineral exploration.

CleanTech Vanadium Mining Corp. has engaged Mercator Geological Services to prepare an independent technical report on its Campbell-Crotser fluorspar project in Kentucky, following National Instrument 43-101 standards. The report will detail geology,...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App